# A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

> **NCT03406156** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 120 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)

## Interventions

- **DRUG:** Obinutuzumab
- **DRUG:** Bendamustine
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT03406156
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-10
- **Primary completion:** 2021-10-12
- **Final completion:** 2023-07-12
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2024-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03406156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03406156, "A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03406156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*